These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31412122)

  • 21. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera.
    Draper E; Bissett SL; Howell-Jones R; Edwards D; Munslow G; Soldan K; Beddows S
    Vaccine; 2011 Nov; 29(47):8585-90. PubMed ID: 21939712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
    Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
    Gene; 2021 May; 782():145533. PubMed ID: 33636291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unveiling the seroprevalence of human papillomavirus in Guangdong, China: Implications for vaccination strategies.
    Hu X; Chen Y; Lin W; Ruan Q; Chen H; Li X; Deng Y; Liang C; Lin H; Zeng L; Sun N; Zhao W; Chen L; Yang Y; Sun L; He J; Sun J
    J Med Virol; 2024 Sep; 96(9):e29910. PubMed ID: 39228341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies.
    Godi A; Vaghadia S; Cocuzza C; Miller E; Beddows S
    Microbiol Spectr; 2022 Jun; 10(3):e0077922. PubMed ID: 35475682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of high-risk HPV and its genotypes-Implications in the choice of prophylactic HPV vaccine.
    Suresh A; Suresh P; Biswas R; Rajanbabu A; Sreedhar S; Biswas L
    J Med Virol; 2021 Aug; 93(8):5188-5192. PubMed ID: 33851736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
    Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
    Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.
    Scherpenisse M; Schepp RM; Mollers M; Meijer CJ; Berbers GA; van der Klis FR
    PLoS One; 2013; 8(9):e74797. PubMed ID: 24058629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.
    Pastrana DV; Gambhira R; Buck CB; Pang YY; Thompson CD; Culp TD; Christensen ND; Lowy DR; Schiller JT; Roden RB
    Virology; 2005 Jul; 337(2):365-72. PubMed ID: 15885736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
    Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
    Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
    Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
    Gambhira R; Karanam B; Jagu S; Roberts JN; Buck CB; Bossis I; Alphs H; Culp T; Christensen ND; Roden RB
    J Virol; 2007 Dec; 81(24):13927-31. PubMed ID: 17928339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16.
    Pastrana DV; Vass WC; Lowy DR; Schiller JT
    Virology; 2001 Jan; 279(1):361-9. PubMed ID: 11145917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity.
    Li Z; Song S; He M; Wang D; Shi J; Liu X; Li Y; Chi X; Wei S; Yang Y; Wang Z; Li J; Qian H; Yu H; Zheng Q; Yan X; Zhao Q; Zhang J; Gu Y; Li S; Xia N
    Nat Commun; 2018 Dec; 9(1):5360. PubMed ID: 30560935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?
    Vorsters A; Van Damme P; Bosch FX
    Int J Infect Dis; 2019 Nov; 88():110-112. PubMed ID: 31521851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
    Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
    Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
    Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
    PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of the benefits and potential issues of the nonavalent HPV vaccine.
    Mariani L; Preti M; Cristoforoni P; Stigliano CM; Perino A
    Int J Gynaecol Obstet; 2017 Mar; 136(3):258-265. PubMed ID: 28087890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal Structures of Two Immune Complexes Identify Determinants for Viral Infectivity and Type-Specific Neutralization of Human Papillomavirus.
    Li Z; Wang D; Gu Y; Song S; He M; Shi J; Liu X; Wei S; Li J; Yu H; Zheng Q; Yan X; Baker TS; Zhang J; McLellan JS; Li S; Xia N
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids.
    Handisurya A; Schellenbacher C; Haitel A; Senger T; Kirnbauer R
    Br J Cancer; 2016 Feb; 114(4):409-16. PubMed ID: 26867163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.